Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Sana Biotechnology, Inc. shareholders approved Election of three Class II directors to serve until 2026 at the 2023-06-08 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-08
Exact text from the filing
Proposal 1: The Company’s stockholders elected all the nominees to serve as Class II directors of the Company’s Board of Directors, each to serve for a three-year term expiring at the Company’s 2026 annual meeting of stockholders or until his or her respective successor is duly elected and qualified, by the votes set forth in the table below: Nominees For Withheld Broker Non-Votes Hans E. Bishop 108,928,064 19,856,165 14,296,363 Robert Nelsen 111,403,976 17,380,253 14,296,363 Alise S. Reicin, M.D. 110,664,981 18,119,248 14,296,363
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Sana Biotechnology, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2023 at the 2023-06-08 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-08
Exact text from the filing
Proposal 2: The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, by the votes set forth in the table below: For Against Abstain 142,770,600 184,749 125,243
View on SEC.gov